Moleculin Biotech, Inc. (MBRX) stock forecast and price target
Price $7.87 · data as of November 13, 2026
12-month price target
Average target$240.00
Upside / downside+2949.6%
Analysts3
ConsensusNone
Low $40.00Average $240.00High $620.00
Gold marker: average target · white marker: today’s price ($7.87)
Analyst ratings
Strong buy 1Buy 2Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-65.33 | — | $0 |
| Next fiscal year ends December 31, 2027 | $-23.40 | — | $0 |
| Next quarter ends December 31, 2026 | $-8.53 | — | $0 |
| Quarter after ends March 31, 2027 | $-8.20 | — | $0 |
Consensus of the analysts covering Moleculin Biotech, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.
Frequently asked questions
What is the Moleculin Biotech stock price target?
The average 12-month target from 3 analysts is $240.00, 2949.6% above the current price of $7.87 Targets range from $40.00 to $620.00.
Is Moleculin Biotech a buy according to analysts?
The consensus rating is “None” (1 strong buy, 2 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Moleculin Biotech expected to earn?
Analysts expect EPS of $-65.33 for the fiscal year ending December 31, 2026 and $-23.40 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.